The primary conclusion of the trial was that low-dosage lithium did not provide any additional benefit beyond guideline-driven care. Only one-quarter of the patients in either group achieved sustained remission. The two groups of participants had similar scores on secondary outcome measures of mood symptoms, functioning, and suicidal ideation. Twenty-one percent of the lithium-plus-OPT patients discontinued lithium, compared with only 2% of the OPT patients who elected to discontinue their mood stabilizers. Thus, even with low to moderate dosages of lithium, problems with adherence remained. In both groups, patients had an average of 2.6 prescriptions in addition to the lithium for the lithium-plus-OPT group. The one intriguing difference between the treatment groups was that the lithium-treated patients were less likely to receive an atypical antipsychotic. Given that the lithium-plus-OPT group reported significantly more manic or hypomanic episodes in the year before the randomized study than the OPT group (5.2 and 3.2, respectively), this finding may merit follow-up investigation.